Met protein and hepatocyte growth factor (HGF) in papillary carcinoma of the thyroid: evidence for a pathogenetic role in tumourigenesis

被引:34
|
作者
Ruco, LP
Stoppacciaro, A
Ballarini, F
Prat, M
Scarpino, S
机构
[1] Univ La Sapienza, Dipartimento Med Sperimentale & Patol, I-00161 Rome, Italy
[2] Univ Piemonte Orientale A Avogadro, Dipartimento Sci Med, Novara, Italy
来源
JOURNAL OF PATHOLOGY | 2001年 / 194卷 / 01期
关键词
thyroid; papillary carcinoma; HGF; MET protein; tumour; invasiveness; dendritic cells;
D O I
10.1002/path.847
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In the last 10 years, evidence has accumulated that overexpression of Met protein is a distinguishing feature of almost every case of well-differentiated papillary carcinoma. Increased expression of the protein is probably due to enhanced transcription of the MET gene and/or to post-transcriptional mechanisms. So far, alterations of the MET gene have not been recognized, but evidence has been provided that activated R.-IS and RET can cause accumulation of MET RNA. Thus, the possibility exists that dysregulation of MET is the final result of different molecular pathways capable of inducing thyroid cell transformation; RET rearrangements might account for some of the cases, but the demonstration that the majority of papillary carcinomas do not have recognized alterations of the RET gene strongly suggests that MET gene dysregulation can also be achieved through other molecular pathways. Dysregulation of MET causes marked accumulation of Met protein in tumour cells that is promptly detected by immunohistochemistry. Thus, overexpression of Met protein might represent an immunohistochemical marker of papillary carcinoma, potentially helpful in problematic cases, but caution is required; moderate expression of Met protein is observed in non-neoplastic thyroid diseases, such as Graves' and Hashimoto's thyroiditis, and reagents active on paraffin sections may have a low affinity and/or low specificity for Met protein, leading to artifactual staining. Met protein-positive papillar? carcinoma cells may produce hepatocyte growth factor (HGF) and may activate HGF through the urokinase-type plasminogen activator (uPA) bound to urokinase-type plasminogen activator receptor (uPA-R), Thus, papillary carcinoma cells possess the molecular machinery necessary for a productive HGF/ Met interaction. In vitro studies have demonstrated that HGF enhances the motility and invasiveness of tumour cells and induces the synthesis and release of chemokines active in the recruitment of dendritic cells. These observations provide a rational basis for the understanding of two distinguishing features of papillary carcinoma. First, the tumour is often characterized by early metastatic spread to regional lymph nodes and by multifocal involvement of the gland, which suggests highly invasive behaviour. Second, a prominent peritumoral inflammatory reaction is often observed, which suggests cross-talk between tumour cells and the immune system. Copyright (C) 2001 John Wiley & Sons, Ltd.
引用
收藏
页码:4 / 8
页数:5
相关论文
共 50 条
  • [21] Hepatocyte growth factor (HGF), HGF activator, and c-Met in synovial tissues in rheumatoid arthritis and osteoarthritis
    Nagashima, M
    Hasegawa, J
    Kato, K
    Yamazaki, J
    Nishigai, K
    Ishiwata, T
    Asano, G
    Yoshino, S
    JOURNAL OF RHEUMATOLOGY, 2001, 28 (08) : 1772 - 1778
  • [22] Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma
    Xie, Qian
    Bradley, Robert
    Kang, Liang
    Koeman, Julie
    Ascierto, Maria Libera
    Worschech, Andrea
    De Giorgi, Valeria
    Wang, Ena
    Kefene, Lisa
    Su, Yanli
    Essenburg, Curt
    Kaufman, Dafna W.
    DeKoning, Tom
    Enter, Mark A.
    O'Rourke, Timothy J.
    Marincola, Francesco M.
    Vande Woude, George F.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (02) : 570 - 575
  • [23] Hepatocyte growth factor (HGF) and c-Met expression in metastatic endometrial cancer
    Brieieva, O.
    Movchan, O.
    Buchynska, L.
    ANNALS OF ONCOLOGY, 2021, 32 : S1352 - S1352
  • [24] The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment
    Parikh, Rahul A.
    Wang, Peng
    Beumer, Jan H.
    Chu, Edward
    Appleman, Leonard J.
    ONCOTARGETS AND THERAPY, 2014, 7 : 969 - 983
  • [25] The expression of hepatocyte growth factor (HGF) and MET receptor in pancreatic ductal carcinomas (PDCs)
    Sessa, F
    Bisoni, D
    Billo, P
    Chiaravalli, AM
    Bonato, M
    Capella, C
    MODERN PATHOLOGY, 1998, 11 (01) : 156A - 156A
  • [26] CELLULAR DISTRIBUTION OF HEPATOCYTE GROWTH FACTOR (HGF) AND HGF RECEPTOR (C-MET) IN CHRONIC MYELOID LEUKEMIA
    Cerny-Reiterer, S.
    Aichberger, K.
    Herrmann, H.
    Muellauer, L.
    Hoermann, G.
    Mayerhofer, M.
    Sillaber, C.
    Valent, P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 334 - 334
  • [27] EXPRESSION OF HEPATOCYTE GROWTH-FACTOR (HGF) AND ITS RECEPTOR, THE C-MET PROTOONCOGENE, IN PROSTATIC-CARCINOMA
    HUMPHREY, PA
    ZHU, X
    SWANSON, P
    ZARNEGAR, R
    RATLIFF, T
    DAY, M
    LABORATORY INVESTIGATION, 1994, 70 (01) : A76 - A76
  • [28] Ontogeny of hepatocyte growth factor and c-met/hgf receptor in rat pancreas
    Calvo, EL
    Boucher, C
    Pelletier, G
    Morisset, J
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 229 (01) : 257 - 263
  • [29] HEPATOCYTE GROWTH-FACTOR SCATTER FACTOR (HGF/SF) IN EARLY DEVELOPMENT - EVIDENCE FOR A ROLE IN NEURAL INDUCTION
    BRONNERFRASER, M
    TRENDS IN GENETICS, 1995, 11 (11) : 423 - 425
  • [30] The Hinge (linker) region of the Hepatocyte Growth Factor (HGF) peptide sequence can act as Hepatocyte Growth Factor/c-Met inhibitor
    Kawas, Leen H.
    Harding, Joseph W.
    Yamamoto, Brent J.
    Wright, John W.
    CANCER RESEARCH, 2011, 71